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Abstract
Hospital- and community-acquired, complicated skin and soft tissue infections, often attributed to Staphylococcus aureus
and Streptococcus pyogenes, present a significant health burden that is associated with increased health care costs and
mortality. As these two species are difficult to discern on diagnosis and are associated with differential profiles of drug
resistance, the development of an efficacious antibacterial agent that targets both organisms is a high priority. Herein we
describe a structure-based drug development effort that has produced highly potent inhibitors of dihydrofolate reductase
from both species. Optimized propargyl-linked antifolates containing a key pyridyl substituent display antibacterial activity
against both methicillin-resistant S. aureus and S. pyogenes at MIC values below 0.1 mg/mL and minimal cytotoxicity against
mammalian cells. Further evaluation against a panel of clinical isolates shows good efficacy against a range of important
phenotypes such as hospital- and community-acquired strains as well as strains resistant to vancomycin.
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Introduction
Staphylococcus aureus is a major cause of hospital-acquired
infections, most frequently associated with the bloodstream, skin
and soft tissue, ventilator-assisted pneumonia and catheters. The
increasing frequency of infections caused by methicillin-resistant S.
aureus (MRSA) is of particular concern, especially in the United
States where the prevalence is more than 55% in the intensive care
unit [1] and the incidence causes longer hospital stays, higher costs
and higher risk of death [2]. Community-acquired MRSA (CA-
MRSA), genotypically distinct from HA-MRSA, has also now
become an established threat among patients without traditional
risk factors [3,4].
While vancomycin is the preferred treatment for MRSA
infection in hospitals, vancomycin-intermediate S. aureus isolates
(VISA) and vancomycin-resistant S. aureus (VRSA) strains have
been reported in the US [5,6] since 2002. Many strains of S. aureus,
including new strains of CA-MRSA, show sensitivity to trimeth-
oprim-sulfamethoxazole (TMP-SMZ). Unfortunately, resistance to
TMP-SMZ among staphylococci has been observed in Australia
and the United States since the early 1980s. Surveys from a
collection of strains show that 28% of MRSA isolates are TMP-
resistant and 35% are SMZ-resistant [7]. The importance of
advancing improved antifolates to target MRSA is widely
recognized and prompted the development of iclaprim, a highly
potent antibiotic against Gram-positive bacteria [8,9,10]. Iclaprim
reached Phase III clinical trials but was denied approval in 2009
pending additional clinical data to demonstrate efficacy and safety
[11].
In addition to S. aureus, the Gram-positive bacteria Streptococcus
pyogenes is a major cause of complicated skin and skin structure
infections (SSTI). Reliably distinguishing between infections
caused by these two agents is difficult because of overlaps in
clinical presentation [12,13]. Unfortunately, the spectrum of
agents that may be effective against both S. aureus and S. pyogenes
is limited by resistance. While S. pyogenes is frequently treated with
beta-lactams, S. aureus shows widespread resistance to this class
[5,14]. Likewise, both strains can be resistant to macrolides
[6,15,16]. Therapeutics with activity against MRSA and S. pyogenes
would be ideal agents for treating SSTI.
Dihydrofolate reductase (DHFR) is a critical enzyme in the
recycling of folate cofactors that are essential for the synthesis of
deoxythymidine monophosphate and several amino acids. Since
inhibition of DHFR depletes the pool of available thymidine, it has
proven to be an excellent drug target for rapidly proliferating
bacteria, protozoa and cancer cells. Despite the validation of
DHFR as a drug target, TMP remains the only approved
antibacterial inhibitor, targeting important pathogens such as
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7MRSA for which it displays bactericidal activity [8,17,18]. Many
pathogens have DHFR enzymes that are naturally resistant to
TMP and several others are affected by point mutations that lead
to TMP resistance.
Using high resolution structural information, we have developed
a new class of antifolates characterized by a unique propargylic
linker that shows activity against an expanded set of enzymes from
important pathogens. Compounds in this series were shown to
exhibit potent inhibition of wild-type MRSA DHFR as well as a
critical resistance mutant, F98Y, known to introduce TMP
insensitivity [19]. We anticipated that further evolution of this
series could lead to compounds that are highly potent against wild-
type MRSA and S. pyogenes DHFR. Herein, we present a new
generation of propargyl-linked inhibitors with a critical pyridyl
substitution that possess significant antibacterial activity (MIC
values of 0.01 mg/mL and 0.09 mg/mL against MRSA and S.
pyogenes, respectively). Crystal structures of representative members
reveal productive contacts with active site residues and evaluation
against a panel of clinical isolates of MRSA shows a spectrum of
activity against clinically relevant phenotypes.
Results and Discussion
Previous work had shown that a meta-biphenyl series of
propargyl-linked antifolates (Figure 1a) were very promising
inhibitors of the wild-type and F98Y mutant of S. aureus DHFR
[19]. Specifically, compound 1 (Figure 1b) was the most potent in
the series with an IC50 value of 42 nM against wild-type SaDHFR
(Table 1) and moderate level of antibacterial activity (MIC value of
5.8 mg/mL, see Table 2). Further evaluation of this compound
against the S. pyogenes DHFR enzyme reveals an IC50 value of
190 nM, suggesting that a compound based on the propargyl
design could potentially target both enzymes. Importantly,
compound 1 displays very good antibacterial activity against S.
pyogenes with a MIC value of 0.1 mg/mL, demonstrating that S.
pyogenes is also sensitive to these antifolate inhibitors. Furthermore,
mammalian cytotoxicity against MCF-10 cells shows an eight-fold
and 484-fold selectivity for MRSA and S. pyogenes, respectively. In
order to advance this class of compounds, we sought to improve
the antibacterial activity against MRSA without compromising the
activity against S. pyogenes while ideally reducing cytotoxicity.
Two strategies to improve the activity against MRSA emerge.
One strategy focuses on improving both potency and selectivity of
enzyme inhibition while a complementary strategy focuses on
striking a better balance between solubility and permeability for
these hydrophobic compounds. Enacting either of these strategies
is greatly facilitated by obtaining structural information for the
complex with the lead compound 1, presented here (Figure 1c),
and related congeners [19,20,21]. Determination of a co-crystal
structure of SaDHFR:NADPH:1 (PDB ID: 3F0S; statistics are
listed in Supplementary Information) reveals a number of regions
for potential modification. Specifically, hydrophobic contacts
between the C6 substituent on the pyrimidine ring and Val 31
and Leu 28 as well as potential interactions between B-ring
substituents and Ser 49 or the ribose of NADPH can be optimized.
Although the propargylic methyl group on compound 1 appears to
form van der Waals interactions with Phe 92 and Thr 46, it may
also contribute to steric crowding that can be relieved by
elimination of the methyl group, which would also decrease the
hydrophobicity of the compounds. In addition to these pockets
deep within the active site, it seemed attractive to optimize
interactions between the distal C-ring and the opening of the
active site that is exposed to solvent in order to improve both
affinity and solubility. In previous optimization, it was shown that
incorporation of the aromatic C-ring greatly enhanced potency by
providing van der Waals contacts with Leu 54, Ile 50, Leu 28 and
Val 31. However, from analysis of the structures, it is clear that
only a portion of the phenyl ring makes productive hydrophobic
contacts and that the C30-C40-C50 region projects toward the
solvent interface and Arg 57, thus introducing destabilizing
interactions. The effect of these destabilizing interactions are
more pronounced with incorporation of a C40 methyl group
(compound 2 in Table 1; IC50=410 nM). Thus, the design of
more efficacious compounds incorporates aspects to increase
affinity and solubility.
We have developed a modular synthetic approach to these
propargyl-linked antifolates that relies on two versatile palladium-
catalyzed cross-coupling reactions to efficiently assemble the
inhibitors from three variable fragments [22,23]. Characterization
and purity data for all new inhibitors is included in Supporting
Information S1. Three new biphenyl derivatives were prepared
along analogous lines to give the final inhibitors in very good yield
Figure 1. Propargyl-linked antifolates potently bind S. aureus DHFR. a) Depiction of a general scaffold for the propargyl-linked antifolates
with the pyrimidine ring (A), phenyl ring (B) and aryl ring (Ar) shown along with possible positions for substitutions (R6,R P,R 29 and R39) b) Illustration
of compound 1, a biphenyl propargyl-linked antifolate, with labeled atom positions b) Active site depiction from the structure of the
SaDHFR:NADPH:1 ternary complex showing active site residues (orange), NADPH (magenta) and compound 1 (blue).
doi:10.1371/journal.pone.0029434.g001
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a inhibit the S. aureus and S. pyogenes DHFR enzymes.
Number Ar R6 RP R29 R39 IC50 (nM) Selectivity
Sa
b Sp
b Human
b (h/Sa)
c (h/Sp)
c
1 3,5-dimethyl phenyl Me Me H OMe 4262 190615 750661 8 4
2 4-methyl phenyl Me Me H OMe 410636 350644 1400615 3 4
7 phenyl Et H OMe H 2.460.2 5.960.2 300610 125 51
8 phenyl Et H H H 2861.7 2661.7 290636 10 11
9 phenyl Et H H OMe 5962.3 5261.7 14061.0 2.4 3
10 phenyl Me Me OMe H 75642 3 61.5 97610 1.3 4
11 phenyl Et Me OMe H 6765.5 2662.5 100610 1.5 4
24 4-pyridyl Me Me H OMe 2662 16069 150068 58 9.4
25 4-pyridyl Et Me H OMe 1961 180619 1300611 68 7.2
26 4-pyridyl Et H OMe H 2161.0 1961.3 330612 16 17
27 4-pyridyl Et H H OMe 1262.4 2864.0 6165.7 5 2
28 4-pyridyl Et H H H 2060.5 3061.7 520623 26 17
31 morphilino Me Me H OMe 29622 6 644 0 0 640 14 15
36 3-pyridyl Et H H H 3360.5 4764.6 290615 9 6
37 4-pyrimidinyl Et H H H 3561.1 2361.2 160613 5 7
TMP 23 13000 198000 8600 15
aThe generalized scaffold for the propargyl-linked inhibitors is shown in Figure 1a.
bIC50 values against the DHFR enzymes are reported in nM and represent the average of at least three measurements.
cSelectivity is calculated as IC50 (human)/IC50 (pathogen).
doi:10.1371/journal.pone.0029434.t001
Table 2. Evaluation of antibacterial and cytotoxicity activity of propargyl-linked antifolates.
Cmpd #
MIC
MRSA
a
MIC
MRSA
b+
FCS
MIC
S.pyogenes
MIC
S. pyogenes+FCS
c
IC50
MCF-10
(mM)
IC50 HepG2
(mM)
Selectivity
d
MRSA
Selectivity
S. pyogenes
1 5.76 (16) ND 0.097 (0.25) ND 47 ND 3 188
2 0.71 (2) ND 0.024 (0.064) ND 55 ND 28 859
7 0.18 (1) ND 0.006 (0.016) ND 67 ND 67 4,187
8 0.66 (2) 5.2 (16) 0.66 (2) 2.6 (8) 32 ND 16 16
9 0.18 (0.5) 1.4 (4) 0.18 (0.5) 0.72 (2) 199 ND 398 398
10 0.72 (2) 11.4 (32) 0.18 (0.5) 5.7 (16) 38 94 19 76
11 0.74 (2) 11.9 (32) 0.74 (2) 6 (16) 54 77 27 27
24 0.04 (0.125) 0.09 (0.25) 0.04 (0.125) 0.09 (0.25) 220 233 1,760 1,760
25 0.09 (0.5) ND 0.012 (0.032) ND 85 171 170 2,656
26 0.02 (0.064) 0.09 (0.25) 0.04 (0.125) 0.09 (0.25) 217 199 3,391 1,736
27 0.04 (0.125) 0.09 (0.25) 0.04 (0.125) 0.09 (0.25) 409 465 3,272 3,272
28 0.08 (0.25) 0.16 (0.5) 0.04 (0.125) 0.09 (0.25) 475 .500 1,900 3,800
31 1.5 (4) 2.94 (8) 2.94 (8) 2.94 (8) 462 494 116 58
36 0.041 (0.125) ND 0.08 (0.25) ND .500 .500 .4,000 .2,000
37 0.16 (0.5) 0.16 (0.5) 0.16 (0.5) 0.16 (0.5) .500 ND .1,000 .1,000
TMP 0.14 (0.5) 0.14 (0.5) 0.58 (2) 0.58 (2) ND ND ND ND
aMIC values for MRSA and S. pyogenes are reported in mg/mL (mM).
bMIC values for MRSA in the presence of 10% fetal calf serum (FCS) in mg/mL (mM).
cMIC values for S. pyogenes in the presence of 10% FCS in mg/mL (mM).
dSelectivity values are calculated as IC50 (MCF10)/MIC (pathogen), both values in mM. ND: not determined.
doi:10.1371/journal.pone.0029434.t002
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phenyl boronic acid and the resulting biphenyl aldehyde, 3, was
homologated to the terminal acetylene 4 through a three-step
sequence that involved Wittig homologation to the phenylacetal-
dehyde followed by Ohira-Bestmann condensation to introduce
the alkyne. A Sonogashira coupling to 6-ethyl, 5-iodo, 2,4-
diaminopyrimidine produced the final inhibitor 7 in good yield.
Biphenyl inhibitors 10 and 11 were achieved in a similar fashion
from 4-hydroxybiphenyl. Regioselective bromination followed by
methylation and acetylation gave 5. The methyl ketone was
homologated as previously described and the resultant alkyne 6
was coupled to the appropriate iodo-pyrimidine to yield inhibitors
10 and 11.
The introduction of a basic pyridine moiety into the biphenyl
lead series was easily accomplished by modification of the
previously described route (Figure 3). Suitably substituted
bromo-benzaldehyde and bromo-acetophenone derivatives 12–
15 could be cross-coupled in high yield with 4-pyridyl boronic acid
to deliver biaryls 16–19 that were taken on through the three-step
homologation to give the corresponding alkynes 20–23. The
presence of the basic pyridine group was well tolerated in the final
palladium catalyzed cross-coupling to produce the pyridyl
inhibitor series 24–28 for evaluation.
A final series of inhibitors with alternative heterocyclic
functionality were accessed by further modification of this flexible,
convergent route developed for this class of antifolates (Figure 4).
Utilizing an amine in the coupling allowed for the introduction of
a morpholine ring 29 while different boronate coupling partners
permitted introduction of an isomeric 3-pyridyl or pyrimidinyl
substituent as in 32/33. Homologation to the terminal alkyne and
cross-coupling to the iodopyrimidine building blocks delivered the
final series of inhibitors 31, 36 and 37.
As solubility is an important consideration in drug development,
a preferred lead series would exhibit solubility values greater than
20 mg/mL [24]. The heterocyclic series of derivatives (24–28, 31,
36, 37) were predicted to show improved solubility relative to the
biphenyl series. In fact, solubility values were experimentally
determined for a representative compound, 25, and found to be in
an acceptable range (40 mg/mL).
A series of biphenyl derivatives, 7–11, probe the deletion of
both propargylic and C-ring methyl groups, extension of the C6
alkyl group and the role of the B-ring alkoxy substituent. As
predicted from the previous structural analysis, removal of the
hydrophobic branching substituents both at the propargyl position
and the distal aryl ring is well tolerated. Likewise, extension of the
C6 alkyl chain had little impact on enzyme inhibition. However,
the contribution of the B-ring substituent was more pronounced
(compare compounds 7 and 9), with a 29-methoxy proving to be a
more optimal placement, leading to a highly potent (2.4 nM and
5.9 nM) dual inhibitor of both S. aureus and S. pyogenes DHFR.
Interestingly, the structure-activity relationships observed in the
biphenyl series did not directly translate to those analogs
containing heterocyclic systems at ring C. Whereas the propargyl
methyl and B-ring methoxy groups significantly impacted the
activity of the biphenyl series, these substituents showed little effect
in S. aureus DHFR across the heterocyclic series (compounds 24–
28, 31, 36, 37). In S. pyogenes, compounds without a propargyl
methyl group exhibited 9-fold better enzyme inhibition (compare
compounds 25 and 27). In order to understand the divergence
between activity in the biphenyl and heterocyclic series, crystal
structures of S. aureus DHFR bound to compounds 7 or 25 were
determined.
Crystal structures of SaDHFR bound to NADPH and
compounds 7 and 25
The structures of S. aureus DHFR bound to NADPH and 7
(Figure 5a; PDB ID: 3SH2; statistics in Table S1) or 25 (Figure 5b;
PDB ID: 3SGY) were compared to the structure of S. aureus DHFR
bound to compound 1. Despite similarities between the three
structures (the RMSD of Ca atoms is approximately 0.24 A ˚), there
are several differences in ligand and residue conformations that
explain the structure-activity relationships observed in the enzyme
activity data (electron density depictions are shown in Figure S1).
Comparison of the structures of S. aureus DHFR:NADPH:7 and S.
aureus DHFR:NADPH:1 shows minimal changes in the orientation
of the three aryl rings present in both inhibitors. However, a major
difference that accounts for the 18-fold improvement in potency
for compound 7 against S. aureus DHFR is the presence of a
hydrogen bond (3.5 A ˚) between the 29-methoxy substituent in
compound 7 and the hydroxyl group of Ser 49, an interaction that
is precluded with the 39-methoxy in compound 1.
Comparison of the structures of S. aureus DHFR:NADPH:25
and S. aureus DHFR:NADPH:1 (Figure 5c) reveals a dramatic
reorientation of the hydrophobic regions of the pyridyl series
relative to the parent biphenyl analogs. In fact, a different
enantiomer of pyridine 25 preferentially crystallizes relative to the
enantiomer observed with 1. This new configuration forces a
change in conformation for the nicotinamide ring of NADPH in
order to maintain p-p stacking as well as a change in the
conformation of Ile 50 that interacts with the proximal aryl ring.
The stabilizing solvation of the pyridyl nitrogen at the opening of
Figure 2. The synthesis of biphenyl analogs delivers compounds 7, 10 and 11. (a) PhB(OH)2, Pd(PPh3)2Cl2,C s 2CO3, dioxane, 80uC, 91%; (b)
Ph3P=CHOMe, THF; (c) Hg(OAc)2, KI, THF/H2O; (d) dimethyl(1-diazo-2 oxopropyl)phosphonate, K2CO3, MeOH; 72% over 3 steps (e) 6-ethyl, 5-iodo-2,4-
diaminopyrimidine, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 81%; (f) Br2, CCl4, 65%; (g) KOH, MeI, DMSO, 90%; (h) n-butyllithium, acetaldehyde, 53%; (i) MnO2,
94%; (j) Ph3P=CHOMe, THF; (k) Hg(OAc)2, KI, THF/H2O; (l) dimethyl(1-diazo-2 oxopropyl)phosphonate, K2CO3, MeOH; 45% over 3 steps; (m) 6-alkyl, 5-
iodo-2,4-diaminopyrimidine, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 72%.
doi:10.1371/journal.pone.0029434.g002
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compound 1. One consequence of this reorientation is decreased
contact between the B- and C-rings and the active site residues,
which is reflected in the slight attenuation in enzyme inhibition.
Antifolates with pyridyl substituents possess potent
antibacterial activity
Evaluation of these new inhibitors in the propargyl-linked
antifolate series against the targeted pathogens reveals that this
series includes very potent antibacterial agents. Specifically, the
pyridyl containing compounds possess MIC values below 0.1 mg/
mL against both MRSA and S. pyogenes; several compounds possess
superior activity when compared to TMP. Interestingly, evaluating
the compounds in the presence of 10% serum highlighted the
superiority of the pyridyl-substituted compounds relative to the
initial biphenyl class. Whereas compounds containing biphenyl
units (8–11) showed a 8-16-fold increase in the MIC value against
MRSA in the presence of serum, the pyridyl derivatives showed
minimal effect with serum and still maintain MIC values lower
than 0.16 mg/mL (Table 2). The difference in sensitivity between
the two classes with respect to the presence of serum likely reflects
increased protein binding for the very hydrophobic biphenyl
moiety. Addition of a basic nitrogen at this center decreases the
hydrophobic character of this region and may reduce overall
protein binding.
In order to validate that the antibacterial activity is a result of
DHFR inhibition, we generated MRSA mutants resistant to a
representative compound, 24, by growing the organism in the
presence of the inhibitor at ten times the MIC value. These
conditions led to the isolation of resistant colonies that were further
analyzed for changes to the DHFR gene sequence. Direct colony
PCR of the DHFR gene revealed point mutations at the active site
of DHFR, specifically Phe98Tyr, validating that DHFR is the
primary target. Although this is the same point mutation known to
confer resistance to TMP, the resistance frequency for compound
24 is very low (3.9610
210). Additionally, compound 24 inhibits
the growth of a MRSA strain containing the F98Y mutation with a
Figure 3. The synthesis of compounds with a pyridyl ring delivers compounds 24–28. (a) 4-pyridylboronic acid, Pd(PPh3)2Cl2,C s 2CO3,
dioxane, 80uC, 82–89%; (b) Ph3P=CHOMe, THF; (c) Hg(OAc)2, KI, THF/H2O; (d) dimethyl(1-diazo-2 oxopropyl)phosphonate, K2CO3, MeOH; 61–70%
over 3 steps (e) 6-alkyl, 5-iodo-2,4-diaminopyrimidine, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 70–85%.
doi:10.1371/journal.pone.0029434.g003
Figure 4. The synthesis of derivatives with alternative heterocycles delivers compounds 31, 36 and 37. (a) Pd(OAc)2, morpholine,
Cs2CO3, (2-Biphenyl)di-tert-butyl phosphine, benzene, 80uC,92%; (b)Ph3P=CHOMe, THF; (c) Hg(OAc)2, KI, THF/H2O; (d) dimethyl(1-diazo-2-
oxopropyl)phosphonate, K2CO3, MeOH, 57–69% over 3 steps; (e) 6-alkyl, 5-iodo-2,4-diaminopyrimidine, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 68–82%, (f) 3-
pyridylboronic acid, Pd(PPh3)2Cl2,C s 2CO3, dioxane, 80uC, 86%; (g) 4-pyrimidinylboronic acid, Pd(PPh3)2Cl2,C s 2CO3, dioxane, 80uC, 76%.
doi:10.1371/journal.pone.0029434.g004
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TMP that has a MIC value of 16 mg/mL against the F98Y strain
[25].
In order to evaluate whether the compounds are bactericidal or
bacteriostatic, we measured the minimum inhibitory and bacte-
ricidal concentrations (MBC) of compounds 24, 25 and TMP in
strain Staphylococcus aureus subsp. aureus ATCC 44300 (Table 3).
From these results, the MIC values match the MBC values for
compounds 24 and 25, with both values equal to 0.078 mg/mL.
Based on the MBC/MIC ratio of 1.0 for compounds 24 and 25,
which falls within the range of 1.0–4.0 cited for bactericidal
antibiotics [26], there is some indication that these compounds
may have bactericidal activity. Interestingly, for this strain, the
MBC/MIC ratio for TMP is 2.0, indicating that it, too, may have
bactericidal activity, agreeing with previous evidence [8,17,27].
The heterocyclic series of antifolates are not only potent
antibacterial agents but also possess minimal cytotoxicity when
evaluated against two mammalian cell lines, MCF-10 and HepG2.
Remarkably, the increased antibacterial activity of the heterocyclic
series is not linked to mammalian cell toxicity, despite lower levels
of enzyme selectivity (Table 1) in these derivatives. While the
origin of the reduced cytotoxicity is unclear, one attractive
possibility is that the compounds are sequestered in the lysosome.
It has been shown that weakly basic compounds with a clogP value
greater than 2 are subject to ion-trapping in the acidic
environment of the lysosome [28,29]. As the pyridyl containing
analogs possess an additional basic nitrogen relative to the
biphenyl series, they may have a greater propensity to accumulate
in the lysosome, therefore minimizing inhibition of cytosolic
mammalian DHFR. In fact, the compounds with a biphenyl at the
C-ring position show a greater degree of cytotoxicity with IC50
values between 32–67 mM. Interestingly, lysosomal sequestration
of antifolates has been previously reported as a mechanism of
resistance in cancer chemotherapy [30,31].
Profiles against clinical isolates of MRSA
As MRSA has globally evolved into a plethora of strains with
varying phenotypes, it is important to evaluate the effects of
promising compounds against a variety of clinically relevant
isolates. Six propargyl-linked antifolates (24–28, 36; Fig. 6) with
the strongest antibacterial activity against S. aureus were selected
for further evaluation against nine clinical isolates (Table 4). Of
these isolates one strain is TMP-SMZ-resistant, two strains
represent USA300 CA-MRSA, three strains represent USA100
HA-MRSA, one strain is HA-MRSA, and two strains are
vancomycin-intermediate S. aureus (VISA; Mu3 and Mu50). The
antibacterial effects of the propargyl-linked compounds were
compared with the effects of vancomycin and TMP:SMZ controls.
In all nine strains, the antibacterial activity of the propargyl-linked
antifolates exceeded the activity of vancomycin. In eight strains,
with the exception of one USA100 HA-MRSA strain, the
antibacterial activity of the propargyl-linked antifolates also
exceeded that of TMP:SMZ.
Conclusions
Skin and soft tissue infections caused by S. aureus and S. pyogenes
are a major health threat and as such, new antibiotics that treat
both of these infections are critically needed. Using a structure-
based approach, a series of propargyl-linked antifolates were
designed, synthesized and shown to possess highly potent
antibacterial activity against both MRSA and S. pyogenes. The
incorporation of additional basic heterocycles not only improved
the solubility of the compounds but also dramatically lowered
mammalian cytotoxicity. Evaluation against a panel of clinical
isolates reveals that the pyridyl-containing analogs are potent
inhibitors of HA-MRSA, CA-MRSA and VISA strains at levels
that exceed vancomycin or TMP-SMZ.
Materials and Methods
Enzyme Expression and Purification
S. aureus DHFR was cloned, expressed and purified as previously
described [19]. Briefly, the DHFR gene was inserted into vector
pET41 with a His8 tag for purification. The protein was expressed
in E. coli BL21 (DE3) cells. The S. aureus DHFR protein was
purified from all other proteins in the lysate, including E. coli
DHFR, using nickel-affinity chromatography and desalted into
20 mM Tris (pH 8.0), 20% glycerol, 0.1 mM EDTA, 2 mM DTT
using a PD-10 column (GE Healthcare). The protein was
concentrated to ,5 mg/mL. S. pyogenes DHFR was cloned using
PCR from genomic DNA and inserted in vector pET-41. The
protein was expressed and purified using the same procedures as
detailed for S. aureus DHFR.
Figure 5. Depictions of S. aureus DHFR bound to ligands reveal interactions with active site residues. S. aureus DHFR is shown bound to
NADPH (magenta) and a) compound 7 (purple), b) compound 25 (green) and c) a superposition of compounds 1 (blue) and 25 (green), as
determined from crystal structures.
doi:10.1371/journal.pone.0029434.g005
Table 3. Evaluation of Minimum Bactericidal Concentrations.
Inhibitor
MIC value
(mg/mL)
MBC value
(mg/mL) Ratio MBC/MIC
TMP 0.625 1.25 2.0
24 0.078 0.078 1.0
25 0.078 0.078 1.0
doi:10.1371/journal.pone.0029434.t003
Potent Antifolates for SSTI
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Enzyme inhibition assays were performed by monitoring the
rate of NADPH oxidation by the DHFR enzyme at an absorbance
of 340 nm over five minutes. Assays were performed in the
presence of saturating concentrations of NADPH (100 mM) and
initiated with dihydrofolate (1 mM). All assays were completed at
25uC in a buffer containing 20 mM TES pH 7.0, 50 mM KCl,
10 mM 2-mercaptoethanol, 0.5 mM EDTA and 1 mg/mL BSA.
Inhibition was measured at least three times with inhibitor
concentrations near the IC50 value and the average IC50 value is
reported with a standard deviation.
Evaluation of Antibacterial Activity
Minimum inhibitory concentrations (MIC) were assessed for
S.aureus 13709 and Streptococcus pyogenes using a broth microdilution
approach based on CLSI standards and the use of the colorimetric
reporter Alamar Blue. Stock solutions of standard antibiotics and
test compounds were made at 50 mM in DMSO. Serial two-fold
dilutions of the stocks were prepared in test wells with a maximum
concentration of 500 mM (test concentrations therefore being 500,
250, 126, 64, 32, 16 mM etc.) MIC data are reported in mM and
also converted into mg/mL for comparison to other literature data.
For susceptibility testing, 10 mL of glycerol stock was suspended in
a 10 mL shake flask culture of chemically defined Isosensitest
broth (Oxoid) supplemented with 2% w/v glucose. A sample of the
shake flask culture was diluted to 1610
6 cells/mL in media and
added to 96-well test plates (100 mL per well) containing test
compounds dispensed in DMSO (2 mL) using serial two-fold
dilutions. After an incubation period (30uC) determined from the
strain specific doubling time, a 0.03% w/v aqueous solution of
resazurin (10 mL) was added and the plates were allowed to
incubate; each well was then scored for dye reduction. These
methods reproduce reported MIC values for standard antibiotics
such as kanamycin, vancomycin and chloramphenicol. The MIC
value was taken as the lowest concentration of test compound that
inhibits growth such that less than 1% reduction of resazurin
(lmax 570 nm) to resorufin (lmax 600 nm) was observed.
Evaluation of Mammalian Cell Toxicity
Adherent cell lines were maintained in Eagle’s Minimal
Essential Media (Sigma-Aldrich, St. Louis, MO, USA) with
2 mM glutamine and Earle’s Balanced Salt Solution (HyClone,
Figure 6. Active antifolates are evaluated against clinical isolates of MRSA.
doi:10.1371/journal.pone.0029434.g006
Table 4. Propargyl-linked antifolates inhibit the growth of a panel of MRSA strains (MIC values in mg/mL).
Compound (#) TMP-SMZ
R
USA300
CA-MRSA
USA300
CA-MRSA
USA100 HA-
MRSA
USA100 HA-
MRSA
USA100 HA-
MRSA HA-MRSA
hVISA
a
Mu3
VISA
Mu50
24 0.045 0.045 0.09 2.9 0.045 0.09 0.09 0.045 0.18
25 0.09 0.045 0.09 2.9 0.09 0.09 0.02 0.09 0.09
26 0.04 0.08 0.08 5.3 0.08 0.04 0.08 0.04 0.04
27 0.045 0.045 0.045 2.9 0.045 0.045 0.045 0.045 0.18
28 0.045 0.045 0.045 2.9 0.045 0.045 0.045 0.045 0.09
36 0.045 0.02 0.36 5.76 0.36 0.09 0.36 0.36 0.72
TMP:SMZ
(1:20)
b
1.5/30.5
c 0.4/8 0.75/15 1.5/30.5 0.2/4 0.2/4 0.75/15 0.2/4 0.2/4
Vancomycin 2 1 1 0.5 1 1 1 3 8
ahVISA: heteroresistant vancomycin intermediate S. aureus.
b1:20 reflects the molar ratio of the two components.
cThe two numbers reflect theindividual MIC values for each component of the mixture.
doi:10.1371/journal.pone.0029434.t004
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ate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate
and 10% fetal calf serum. Fetal calf serum used in these assays was
lot matched throughout. All cultures were maintained under a
humidified 5% CO2 atmosphere at 37uC, had media refreshed
twice weekly and were subcultured by trypsinization and
resuspension at a ratio of 1:5 each week. Toxicity assays were
conducted between passages 10–20. Target compound toxicity
was measured by incubating the test compound with the cells for
4 h, washing the cells and finally treating the cells with Alamar
Blue. After 12–24 h, the fluorescence of the reduced dye was
measured. Fluorescence intensity as a function of test compound
concentration was fit to the Fermi equation, using non-linear least
squares regression analysis, to estimate IC50 values.
Crystallization and Structure Determination
S. aureus DHFR was co-crystallized with 1, 7, and 25 using the
hanging drop vaporization method. Protein (12 mg/mL) was
incubated with ligand (1 mM) and NADPH (2 mM) for two hours
on ice. An equal volume of the protein:ligand:NADPH complex
was mixed with an optimized crystallization solution consisting of
15% PEG 10,000, 150 mM sodium acetate, 100 mM MES
pH 6.5, and 5% butyrlactone (Sigma Aldrich). All crystal growth
followed the same procedures and typically yielded crystals within
5–7 days. Crystals were incubated in a cryo-protectant buffer
containing 15% glycerol then flash-cooled with liquid nitrogen.
High resolution data sets were collected at Brookhaven NSLS on
beamline 625.
Data were indexed and scaled used HKL2000. Crystal
structures for all complexes were solved using a model of S. aureus
DHFR bound to folate. The diffraction data for the complex of
SaDHFR:NADPH:1 and the model share the same hexagonal
space group (P6122) and unit cell dimensions, therefore difference
Fourier methods were used to solve the phase problem for these
data. The crystals of SaDHFR:NADPH:7 and SaDHFR:-
NADPH:25 belong to space group P61 and there are two
molecules in the asymmetric unit. Therefore, these structures were
determined by molecular replacement using Phaser [32] The
programs COOT and Refmac5 were used to build and refine the
structure until an acceptable Rfactor and Rfree were achieved (data
and refinement statistics are noted in Table S1). Structure
geometry was evaluated using Procheck and Ramachandran plots.
Solvent was not included in the final models for the crystal
structures of S. aureus DHFR bound to NADPH and compounds 1
and 7.
MBC determination for MRSA strain 43300
Minimal bactericidal concentrations (MBCs) were determined
for Staphylococcus aureus subsp. aureus ATCC 44300 by performing
MIC determinations using the microdilution method according to
CLSI standards [33], then culturing the visibly clear wells (as
confirmed by OD600) onto Isosensitest Agar (ISA; Oxoid) and
growing for 24 hours at 37uC. MBC was defined as the lowest
concentration of inhibitor preventing colony growth on agar plates
[34].
Selection of resistant MRSA colonies
For these experiments, MRSA strain ATCC 43300 was used as
the progenitor strain. Resistant colonies were selected by plating
100 mL of saturated overnight culture (approximately 10
11 CFU/
mL) in triplicate on selective ISA containing 106 MIC
concentration of compound 24 [25]. Selective plates were grown
for 30 hours at 37uC. All colonies resistant to compound 24 were
re-passaged on selective ISA. Direct colony PCR was used to
isolate and amplify the dfrA gene from resistant strains using
methods described in [34]. All PCR products were screened for
point mutations in DHFR by high quality DNA sequencing
(Genewiz). Primers used to detect the dfrA gene contained
restriction enzyme cut sites for NdeI and XhoI in order to ligate
PCR products into the pET41 vector for further validation with
DNA sequencing with the T7 promoter sequencing primer.
Mutation frequencies were calculated based on the sequencing
information provided for each mutant colony.
Supporting Information
Supporting Information S1 Characterization, spectral and
purity data for compounds 7, 10, 11, 24–28, 31 and 36–37.
(DOCX)
Figure S1 Electron density for the active site and ligands,
calculated as Fo-Fc omit maps show a) compound 1 (1.3 s), b)
compound 7 (1.3 s) and c) compound 25 (1.0 s).
(TIF)
Table S1 Statistics for data collection and refinement of crystal
structures.
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